Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

NCT00100243 is registered in ClinicalTrials.gov with PRAECIS Pharmaceuticals Inc. as lead sponsor.

NCT NCT00100243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00100243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
September 30, 2005
Enrollment
22
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer